Benitec Biopharma Inc.
For the period ended Sep 30, 2026. Filed Nov 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 13, 2026
BNTC$9.04-0.6%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Checking your notes…
(in thousands, except par value and share amounts)
| September 30,2026 | June 30,2026 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $176,368 | $179,972 |
| Restricted cash | 114 | 114 |
| Trade and other receivables | — | 4 |
| Prepaid and other assets | 1,622 | 1,595 |
| Total current assets | 178,104 | 181,685 |
| Property and equipment, net | 110 | 178 |
| Deposits | 55 | 55 |
| Prepaid and other assets | 244 | 12 |
| Right-of-use assets | 585 | 693 |
| Total assets | $179,098 | $182,623 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Trade and other payables | $7,962 | $4,295 |
| Accrued employee benefits | 608 | 553 |
| Lease liabilities, current portion | 507 | 496 |
| Total current liabilities | 9,077 | 5,344 |
| Other long-term liabilities | 239 | — |
| Lease liabilities, less current portion | 135 | 266 |
| Total liabilities | 9,451 | 5,610 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value—5,000,000 shares authorized; no shares issued or outstanding at September 30, 2026 and June 30, 2026, respectively | — | — |
| Common stock, $0.0001 par value—160,000,000 shares authorized; 34,889,313 and 34,416,834 shares issued and outstanding at September 30, 2026 and June 30, 2026 respectively | 4 | 3 |
| Additional paid-in capital | 457,237 | 451,695 |
| Accumulated deficit | (286,647) | (273,722) |
| Accumulated other comprehensive loss | (947) | (963) |
| Total stockholders’ equity | 169,647 | 177,013 |
| Total liabilities and stockholders’ equity | $179,098 | $182,623 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.